About Us | Contact Us |        

A Comprehensive Approach to Monitoring and Treating Patients With IBD

A Performance Measures-Based Patient-Centric Approach to IBD
1 AMA PRA Category 1 Credit(s)
Launch Date:
November 30, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, Nurse Practioners, Physican Assistants

Relevant Terms:

Inflammatory Bowel Diseases

Gil Y. Melmed, MD, MS

Gil Y. Melmed, MD, MS 
Director of Clinical Inflammatory Bowel Disease
Associate Professor of Medicine
Cedars-Sinai Medical Center
Los Angeles, CA

Gil Y. Melmed, MD, MS, received his medical degree from Albert Einstein College of Medicine in New York. He completed his residency at Cedars-Sinai Medical Center in Los Angeles and his gastroenterology fellowship at UCLA, where he also received a master's of science in clinical research. He is board certified by the American Board of Internal Medicine in gastroenterology.

Dr. Melmed is director of Clinical Inflammatory Bowel Disease (IBD) and associate professor at Cedars-Sinai Medical Center. His main clinical and research interests are clinical outcomes in IBD (Crohn's disease and ulcerative colitis), including health-related quality of life, post-operative outcomes, vaccination and health maintenance issues in patients with IBD, and quality of care for IBD. He has authored or co-authored more than 70 publications and serves as a review editor for Inflammatory Bowel Disease and as the IBD associate editor for the American Journal of Gastroenterology. He is an active member of the Crohn's and Colitis Foundation of America (CCFA) and co-chairs the CCFA's national Quality of Care Committee, and he is a past chair of the IBD section of the American Gastroenterology Association's Quality Measures Committee.

Adam S. Cheifetz, MD

​Adam S. Cheifetz, MD
Director, Inflammatory Bowel Disease Program, Beth Israel Deaconess Medical Center
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Adam S. Cheifetz, MD, is the director of the Inflammatory Bowel Disease Program at Beth Israel Deaconess Medical Center and an associate professor of medicine at Harvard Medical School. Dr. Cheifetz graduated magna cum laude from Brown University in Rhode Island before earning his MD from Cornell University Medical College in New York. He completed his internship and residency in internal medicine at Yale-New Haven Hospital in Connecticut and his fellowship in gastroenterology at Yale University before serving as the Present-Levison Fellow in Inflammatory Bowel Disease at the Mount Sinai Medical Center in New York.

Dr. Cheifetz specializes in the treatment of Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases (IBD). For the last 8 years, he has been cited in Boston Magazine as one of Boston's "Top Doctors." In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published more than 100 articles and chapters on the subject. Dr. Cheifetz's research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies. He lectures nationally and internationally on IBD and has been involved with the Crohn's and Colitis Foundation of America (CCFA) for more than 10 years on both a regional and national level.

Dr. Cheifetz is actively involved with teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD. He is director of the Harvard Medical School Gastroenterology Clerkship Elective and assistant director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center. In addition, he serves on numerous editorial boards, including Inflammatory Bowel Diseases, Journal of Clinical Gastroenterology, Journal of Crohn's and Colitis, and World Journal of Gastroenterology.

Meenakshi Bewtra, MD, MPH, PhD

Meenakshi Bewtra, MD, MPH, PhD
Assistant Professor
Division of Gastroenterology
University of Pennsylvania School of Medicine
Philadelphia, PA

Meenakshi Bewtra, MD, MPH, PhD, graduated from Yale University and received her medical degree from the University of Pennsylvania. She completed training in internal medicine and a fellowship in gastroenterology with specific training and expertise in inflammatory bowel disease (IBD). While a resident, Dr. Bewtra also completed a Master of Public Health at the Harvard School of Public Health with a specific focus on epidemiology and biostatistics. She completed her PhD at the Center for Clinical Epidemiology and Biostatistics (CCEB) at the University of Pennyslvania, with a focus on the use of discrete choice experiments in IBD.
Dr. Bewtra is an assistant professor in the Division of Gastroenterology and a senior scholar at the CCEB at the University of Pennsylvania. In her role at the CCEB, Dr. Bewtra serves as the primary research mentor for college students, residents, and fellows within the institution's Master of Science in Clinical Epidemiology program. She is a member of the Crohn's & Colitis Foundation of America, American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy, and American College of Gastroenterology, and she has previously served on the executive management board of the AGA Digestive Health Outcomes Registry.
Dr. Bewtra has been conducting epidemiological research in the field of IBD for more than a decade and has authored many articles, editorials, reviews, and book chapters in peer-reviewed and other research publications. She has obtained a K08 National Institutes of Health grant, with a specific focus on outcomes research and discrete choice studies in ulcerative colitis and evaluating medical versus surgical therapies in these patients. She is currently conducting several additional discrete choice studies evaluating IBD patients' risk preferences. Dr. Bewtra is the primary investigator of an IBD biorepository at the University of Pennsylvania in collaboration with the Institute of Immunology. The university and the institute have several ongoing and completed studies and grants related to this work, linking clinical metadata with immunological and microbiological tissue.
1. Compare and contrast the clinical effects of inflammatory bowel disease (IBD) therapies
2. Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity
3. Employ ongoing monitoring strategies assessing treatment goals and implement changes in treatment plans as appropriate
4. Utilize American Gastroenterological Association (AGA) practice measures for the management of IBD patients to slow the disease course and minimize complications

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Celgene, Genentech, Luitpold, Takeda, and UCB (Consulting).
  • Adam S. Cheifetz, MD, has affiliations with AbbVie, Janssen, Pfizer, Prometheus Laboratories, Takeda, and UCB (Consulting); Royalty-Up To Date.
  • Meenakshi Bewtra, MD, MPH, PhD, has affiliations with AbbVie (Consulting) and GlaxoSmithKline (Research).
  • Boris Rozenfeld, MD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests relative to the content to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 1.0 hour
Medium: Internet

There is no fee for this educational activity.

This activity is supported by an independent educational grant from AbbVie Inc.

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above